Cancer and systemic metabolic hormones (e.g., insulin, leptin) caused by overweight, diabetes, or pre-diabetes are closely linked. Yet, this condition that affects millions of cancer patients is being overlooked as the major contributor to cancer progression that it is. What’s worse, many anti-cancer treatments cause metabolic dysfunction which can limit drug effectiveness and even lead to treatment resistance.
SynDevRx – the leader in the emerging field of metabo-oncology – is tackling this urgent and unmet medical need with its clinical drug evexomostat (SDX-7320).